TrialsgrambetaRCTs are beautiful

EARLY TAVR

2025

Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis

In 901 patients with asymptomatic severe aortic stenosis, early TAVR reduced death, stroke or unplanned cardiovascular hospitalisation compared with clinical surveillance.

Result

Efficacy: Death, stroke or unplanned CV hospitalisationHR 0.5

Below 1 favours early TAVR, above 1 favours clinical surveillance.

Event rates
Absolute difference
18.5 points

The absolute difference is derived from the event rates.

Original publication
Subtopic
TAVR
Design
RCT, open-label
Relevance
Important: one of several pillars.
Cited in
ESC 2025 VHD
Source
Généreux P, et al. N Engl J Med. 2025;392(3):217-227.doi 10.1056/NEJMoa2405880

Discussion & critique

No mortality or stroke benefit: the composite is driven by 'soft' hospitalisations, with ~ 70 % crossover from surveillance. Contrasts with the neutral EVOLVED trial.

Discussed in podcasts